The National Acquisition Center of the Department of Veterans Affairs (VA) awarded a single-award Indefinite Delivery Contract (IDC) to Fresenius Kabi, LLC, a foreign-owned pharmaceutical company, for the supply of Bortezomib vials. The $2,237,072.60 contract covers a one-year base period from March 11, 2023, to March 10, 2024, with four one-year option periods. The contract is intended to provide an uninterrupted source of Bortezomib, a cancer treatment drug, to the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The estimated annual requirement is 17,804 vials of Bortezomib. This IDC was awarded as a result of a pre-solicitation notice issued by the VA for an unrestricted procurement of Bortezomib vials, with a tentative solicitation release date of November 9, 2022, and a closing date of November 23, 2022.
The contract supports the federal healthcare systems' pharmaceutical requirements, particularly for critical care injectable medications. Fresenius Kabi, LLC, as a significant supplier of injectable drugs to military and federal facilities, has established itself as a key vendor in the federal medical supply chain. The contract is structured as a delivery order with no specific set-aside designations, allowing the company to provide a diverse array of medical treatments ranging from pain management to emergency medical interventions to various federal agencies.
Generated 2/8/25, 9:02 AM